347 related articles for article (PubMed ID: 19130605)
1. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution.
Mohsin K; Long MA; Pouton CW
J Pharm Sci; 2009 Oct; 98(10):3582-95. PubMed ID: 19130605
[TBL] [Abstract][Full Text] [Related]
2. In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.
Devraj R; Williams HD; Warren DB; Mohsin K; Porter CJ; Pouton CW
Eur J Pharm Sci; 2013 Jul; 49(4):748-60. PubMed ID: 23684915
[TBL] [Abstract][Full Text] [Related]
3. Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.
Mohsin K; Alamri R; Ahmad A; Raish M; Alanazi FK; Hussain MD
Int J Nanomedicine; 2016; 11():2829-38. PubMed ID: 27366063
[TBL] [Abstract][Full Text] [Related]
4. Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion.
Mohsin K
AAPS PharmSciTech; 2012 Jun; 13(2):637-46. PubMed ID: 22547370
[TBL] [Abstract][Full Text] [Related]
5. Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate.
Griffin BT; Kuentz M; Vertzoni M; Kostewicz ES; Fei Y; Faisal W; Stillhart C; O'Driscoll CM; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2014 Apr; 86(3):427-37. PubMed ID: 24184675
[TBL] [Abstract][Full Text] [Related]
6. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
Suys EJA; Chalmers DK; Pouton CW; Porter CJH
Mol Pharm; 2018 Jun; 15(6):2355-2371. PubMed ID: 29659287
[TBL] [Abstract][Full Text] [Related]
7. Choice of nonionic surfactant used to formulate type IIIA self-emulsifying drug delivery systems and the physicochemical properties of the drug have a pronounced influence on the degree of drug supersaturation that develops during in vitro digestion.
Devraj R; Williams HD; Warren DB; Porter CJ; Pouton CW
J Pharm Sci; 2014 Apr; 103(4):1050-63. PubMed ID: 24470073
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
9. Studying the effect of lipid chain length on the precipitation of a poorly water soluble drug from self-emulsifying drug delivery system on dispersion into aqueous medium.
Prasad D; Chauhan H; Atef E
J Pharm Pharmacol; 2013 Aug; 65(8):1134-44. PubMed ID: 23837581
[TBL] [Abstract][Full Text] [Related]
10. Assessment of cell viability and permeation enhancement in presence of lipid-based self-emulsifying drug delivery systems using Caco-2 cell model: Polysorbate 80 as the surfactant.
Bu P; Ji Y; Narayanan S; Dalrymple D; Cheng X; Serajuddin AT
Eur J Pharm Sci; 2017 Mar; 99():350-360. PubMed ID: 28024890
[TBL] [Abstract][Full Text] [Related]
11. 50years of oral lipid-based formulations: Provenance, progress and future perspectives.
Feeney OM; Crum MF; McEvoy CL; Trevaskis NL; Williams HD; Pouton CW; Charman WN; Bergström CAS; Porter CJH
Adv Drug Deliv Rev; 2016 Jun; 101():167-194. PubMed ID: 27089810
[TBL] [Abstract][Full Text] [Related]
12. The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate.
Do TT; Van Speybroeck M; Mols R; Annaert P; Martens J; Van Humbeeck J; Vermant J; Augustijns P; Van den Mooter G
Int J Pharm; 2011 Jul; 414(1-2):118-24. PubMed ID: 21596119
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluation of a self-microemulsifying drug delivery system for the poorly soluble drug fenofibrate.
Cho YD; Park YJ
Arch Pharm Res; 2014 Feb; 37(2):193-203. PubMed ID: 23754165
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of fenofibrate dissolution delivered by a self-microemulsifying drug-delivery system.
Wei JD; Ho HO; Chen CH; Ke WT; Chen ET; Sheu MT
J Pharm Pharmacol; 2010 Dec; 62(12):1685-96. PubMed ID: 21054394
[TBL] [Abstract][Full Text] [Related]
15. Dissolution improvement of solid self-emulsifying drug delivery systems of fenofibrate using an inorganic high surface adsorption material.
Shazly G; Mohsin K
Acta Pharm; 2015 Mar; 65(1):29-42. PubMed ID: 25781702
[TBL] [Abstract][Full Text] [Related]
16. Solubilisation behaviour of poorly water-soluble drugs during digestion of solid SMEDDS.
Vithani K; Hawley A; Jannin V; Pouton C; Boyd BJ
Eur J Pharm Biopharm; 2018 Sep; 130():236-246. PubMed ID: 29981444
[TBL] [Abstract][Full Text] [Related]
17. The in vitro and in vivo evaluation of fenofibrate with a self- microemulsifying formulation.
Xiumin LI; Man GE; Minzi LU; Yinghua J; Dongqin Q
Curr Drug Deliv; 2015; 12(3):308-13. PubMed ID: 26054534
[TBL] [Abstract][Full Text] [Related]
18. Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity.
Jannin V; Chevrier S; Michenaud M; Dumont C; Belotti S; Chavant Y; Demarne F
Int J Pharm; 2015 Nov; 495(1):385-392. PubMed ID: 26364710
[TBL] [Abstract][Full Text] [Related]
19. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.
Williams HD; Sassene P; Kleberg K; Calderone M; Igonin A; Jule E; Vertommen J; Blundell R; Benameur H; Müllertz A; Porter CJ; Pouton CW;
J Pharm Sci; 2014 Aug; 103(8):2441-55. PubMed ID: 24985238
[TBL] [Abstract][Full Text] [Related]
20. Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations.
Sahbaz Y; Williams HD; Nguyen TH; Saunders J; Ford L; Charman SA; Scammells PJ; Porter CJ
Mol Pharm; 2015 Jun; 12(6):1980-91. PubMed ID: 25905624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
